Robert Pirker
Impact in
- Oncology top 0.5%
- Drug Transport and Resistance Mechanisms
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 76
- Lung Cancer Diagnosis and Treatment 37
- Oncology 47
- Drug Transport and Resistance Mechanisms 27
- Cancer Immunotherapy and Biomarkers 6
- Lung Cancer Research Studies 6
- Co-authors
- Martin Filipits (63 shared papers)Thierry Le Chevalier (17 shared papers)Helmut Popper (19 shared papers)Ariane Dunant (12 shared papers)Jean‐Charles Soria (17 shared papers)Jean‐Pierre Pignon (13 shared papers)Kenneth John O'Byrne (10 shared papers)Elisabeth M. Brambilla (15 shared papers)
- Journals
- Lung Cancer (23 papers)Journal of Thoracic Oncology (18 papers)Annals of Oncology (17 papers)European Journal of Cancer (10 papers)Current Opinion in Oncology (9 papers)
- Partner nations
- AustriaUnited StatesGermany
In The Last Decade
Robert Pirker
235 papers receiving 14.3k citations
Robert Pirker's Hit Papers
Peers
Comparison fields: 5 of 92
- Oncology 3.4k
- Pulmonary and Respiratory Medicine 4.8k
- Cancer Research 574
- Internal Medicine 141
- Hematology 451
Countries citing papers authored by Robert Pirker
This map shows the geographic impact of Robert Pirker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Pirker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Pirker more than expected).
Fields of papers citing papers by Robert Pirker
This network shows the impact of papers produced by Robert Pirker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Pirker. The network helps show where Robert Pirker may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Pirker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 248 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy Hit paper breakdown → | 2006 | 1427 |
| 2 | Expression of Multidrug Resistance Gene in Human Cancers Hit paper breakdown → | 1989 | 1146 |
| 3 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Hit paper breakdown → | 2009 | 1123 |
| 4 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC Hit paper breakdown → | 2018 | 530 |
| 5 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2018 | 503 |
| 6 | EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Hit paper breakdown → | 2011 | 489 |
| 7 | 2009 | 330 | |
| 8 | 1991 | 318 | |
| 9 | 2013 | 314 | |
| 10 | 2016 | 301 | |
| 11 | 2012 | 275 | |
| 12 | 2013 | 252 | |
| 13 | Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions Hit paper breakdown → | 2023 | 250 |
| 14 | 2002 | 243 | |
| 15 | 2010 | 243 | |
| 16 | 2016 | 235 | |
| 17 | 2009 | 230 | |
| 18 | 2007 | 218 | |
| 19 | 2015 | 207 | |
| 20 | 2011 | 180 |
About Robert Pirker
Robert Pirker is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hematology, Immunology and Internal Medicine, having authored 248 papers that have together received 14.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (76 papers), Lung Cancer Diagnosis and Treatment (37 papers), Drug Transport and Resistance Mechanisms (27 papers), Erythropoietin and Anemia Treatment (18 papers), Acute Myeloid Leukemia Research (8 papers), Toxin Mechanisms and Immunotoxins (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Lung Cancer Research Studies (6 papers). The work is most often cited by research in Oncology (3.4k citations), Pulmonary and Respiratory Medicine (4.8k citations), Cancer Research (574 citations), Internal Medicine (141 citations) and Hematology (451 citations). Robert Pirker has collaborated with scholars based in Austria, United States and Germany. Frequent co-authors include Martin Filipits, Thierry Le Chevalier, Helmut Popper, Ariane Dunant, Jean‐Charles Soria, Jean‐Pierre Pignon, Kenneth John O'Byrne, Elisabeth M. Brambilla, Joachim von Pawel and Rodryg Ramlau. Their work appears in journals such as Lung Cancer, Journal of Thoracic Oncology, Annals of Oncology, European Journal of Cancer and Current Opinion in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.